Condition: Chronic Limb-Threatening Ischemia · Sponsor: R3 Vascular Inc.
The objective of this prospective, single-blinded, randomized controlled trial is to evaluate the safety and efficacy of the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Approximately 276 subjects will be randomized in a 1:1 ratio. The clinical investigation will be conducted at up to 60 clinical sites globally.
This description comes directly from the study's public registry record.
Megan Hill, B.S. · 1(904)540-3844 · mhill@r3vascular.com
Josh Smale · 1(480)244-9523 · jsmale@r3vascular.com
Always discuss trial participation with your own doctor first.
| NYU Langone Health | New York, New York, United States | Recruiting |
| CUMC/NYP | New York, New York, United States | Recruiting |
| Staten Island University Hospital - Northwell Health | Staten Island, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06071429